Mesenchymal stem cells for the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation

Annals of Hematology

Volumn 88, Issue 3, 2009, Pages 261-266

  Fang, Baijun ^a,b   Song, Yongping ^a   Li, Ning ^a   Li, Jing ^b   Han, Qin ^b   Zhao, Robert Chunhua ^b  

^a HENAN UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Hematopoietic stem cell transplantation; Mesenchymal stem cell; Pure red cell aplasia

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ERYTHROPOIETIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; SEMUSTINE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADIPOSE TISSUE; ADOLESCENT; ADULT; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD TRANSFUSION; CASE REPORT; CHIMERA; CLINICAL EFFECTIVENESS; DIARRHEA; ERYTHROCYTE CONCENTRATE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN DETERMINATION; HLA MATCHING; HUMAN; LEUKEMIA REMISSION; MESENCHYMAL STEM CELL TRANSPLANTATION; PLASMAPHERESIS; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RASH; RETICULOCYTE COUNT; SALVAGE THERAPY;

ABO BLOOD-GROUP SYSTEM; ADOLESCENT; ADULT; BLOOD GROUP INCOMPATIBILITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; RED-CELL APLASIA, PURE; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 59049087835     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0599-0     Document Type: Article

References (25)

1. Worel N, Kalhs P, Keil F, Prinz E, Moser K, Schulenburg A et al (2003) ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation. Transfusion 43:1153-1161 doi: 10.1046/j.1537-2995.2003.00465.x
2. Lee JH, Lee KH, Kim S, Lee JS, Kim SH, Kwon SW et al (2000) Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation. Bone Marrow Transplant 25:179-184 doi: 10.1038/ sj.bmt.1702121
3. Gmür JP, Burger J, Schaffner A, Neftel K, Oelz O, Frey D et al (1990) Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation. Blood 75:290-295
4. Lee JH, Lee JH, Choi SJ, Kim S, Seol M, Kwon SW et al (2002) Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation. Br J Haematol 120:702-710 doi: 10.1046/ j.1365-2141.2003.04128.x
5. Badros A, Tricot G, Toor A, Morris C, Guo C, Munshi N et al (2002) ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion 42:205-209 doi: 10.1046/ j.1537-2995.2002.00027.x
6. Mielcarek M, Leisenring W, Torok-Storb B, Storb R (2000) Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: Evidence for a graft-versus-plasma cell effect. Blood 96:1150-1156
7. Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M et al (1991) Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med 325:1267-1273
8. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F et al (2006) Human mesenchymal stem cells modulate B-cell functions. Blood 107:367-372 doi: 10.1182/blood-2005-07-2657
9. Han Q, Liao L, You S, Deng H, Zhao RC (2005) Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice. DNA Cell Biol 24:458-463 doi: 10.1089/dna.2005.24.574
10. Fang B, Song Y, Zhao RC, Han Q, Cao Y (2007) Treatment of resistant pure red cell aplasia after major ABO-incompatible bone marrow transplantation with human adipose tissue-derived mesenchymal stem cells. Am J Hematol 82:772-773 doi: 10.1002/ajh.20932
11. Cao Y, Sun Z, Liao L, Meng Y, Han Q, Zhao RC (2005) Human adipose tissue-derived stem cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo. Biochem Biophys Res Commun 332:370-379 doi: 10.1016/j.bbrc.2005.05.034
12. Deng W, Han Q, Liao L, Li C, Ge W, Zhao Z et al (2005) Engrafted bone marrow-derived flk-(1+) mesenchymal stem cells regenerate skin tissue. Tissue Eng 11:110-119 doi: 10.1089/ten.2005.11.110
13. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringdén O (2003) Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57:11-20 doi: 10.1046/ j.1365-3083.2003.01176.x
14. Martelli M, Ponchio L, Beguin Y, Meloni G, Mandelli F, Cazzola M (1994) Pure red cell aplasia following peripheral stem cell transplantation: complete response to a short course of high-dose recombinant human erythropoietin. Haematologica 79:456-459
15. Ohashi K, Akiyama H, Takamoto S, Tanikawa S, Sakamaki H, Onozawa Y (1994) Treatment of pure red cell aplasia after major ABO-incompatible bone marrow transplantation resistant to erythropoietin. Bone Marrow Transplantation Team. Bone Marrow Transplant 13:335-336
16. Veelken H, Wäsch R, Behringer D, Bertz H, Finke J (2000) Pure red cell aplasia after allogeneic stem cell transplantation with reduced conditioning. Bone Marrow Transplant 26:911-915 doi: 10.1038/ sj.bmt.1702629
17. Sahovic EA, Flick J, Graham CD, Stuart RK (1991) Case report: Isoimmune inhibition of erythropoiesis following ABO-incompatible bone marrow transplantation. Am J Med Sci 302:369-373 doi: 10.1097/ 00000441-199112000-00009
18. Koç ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AI et al (2000) Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 18:307-316
19. Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI (1995) Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): Implications for therapeutic use. Bone Marrow Transplant 16:557-564
20. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M et al (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363:1439-1441 doi: 10.1016/S0140-6736(04)16104-7
21. Fang B, Song Y, Lin Q, Zhang Y, Cao Y, Zhao RC et al (2007) Human adipose tissue-derived mesenchymal stromal cells as salvage therapy for treatment of severe refractory acute graft-vs.-host disease in two children. Pediatr Transplant 11:814-817 doi: 10.1111/ j.1399-3046.2007.00780.x
22. Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J et al (2007) Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 21:1733-1738 doi: 10.1038/sj.leu.2404777
23. Fang B, Song Y, Liao L, Zhang Y, Zhao RC (2007) Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplant Proc 39:3358-3362 doi: 10.1016/j.transproceed.2007.08.103
24. Fang B, Song YP, Liao LM, Han Q, Zhao RC (2006) Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells. Bone Marrow Transplant 38(5):389-390 doi: 10.1038/sj.bmt.1705457
25. Verholen F, Stalder M, Helg C, Chalandon Y (2004) Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion. Eur J Haematol 73:441-446 doi: 10.1111/j.1600-0609.2004.00320.x